Wird geladen...
Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
First line treatment of patients with castrate resistant prostate cancer (CRPC) primarily involves administration of docetaxel chemotherapy. Unfortunately, resistance to docetaxel therapy is an ultimate occurrence. Alterations in androgen receptor (AR) expression and signaling are associated mechani...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Public Library of Science
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4114978/ https://ncbi.nlm.nih.gov/pubmed/25072314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0103680 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|